Inspire Medical Systems, Inc. (INSP)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
$66.48+6.98%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Maintain adjusted operating margin between 2% and 4% in 2026: FY26 guidance 4.0% to 6.0% vs 2% to 4% target.
Inspire Medical Systems focuses on minimally invasive sleep apnea solutions. Revenue is guided between $825M and $875M for 2026. The company aims to improve profit margins to 2% to 4%. Recent earnings beats show potential for recovery.
Revenue is expected to decline about 3% next year. Profit margins remain below the guided range, with Q1 at 0.2%. The company faces elevated risk and fragile quality amid mixed momentum.
The stock price is about 17% below our valuation level and 11% above the Street median. Analysts expect roughly a 3% revenue decline. Our view sees potential upside if the company meets guidance and margin targets.
Breaks if: adjusted operating margin remains below 2% for FY26
Breaks if: EPS falls below $0.07 in FY26
Breaks if: annual revenue falls below $825 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The company is currently facing challenges related to reimbursement issues but has shown strong recent financial performance and aims for revenue growth in the future.
The market appears to have priced in a low level of fragility, indicating that expectations are somewhat stable. Valuation suggests that INSP is relatively cheap compared to its peers, with a slight expectations gap.
Management is focused on resolving coding and reimbursement uncertainties, which have impacted recent revenue. Although revenue has declined, there is an expectation for improvement in 2027, while operating margins are currently below target but show signs of progress.
The thesis hinges on management's ability to navigate reimbursement challenges and achieve revenue guidance. Additionally, broader sector performance, particularly from major healthcare companies, could influence INSP's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The multi-year view remains intact as INSP works through its challenges while aiming for future growth. Not investment advice.